<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="infections, so far. Keywords Antiviral drugs Protease inhibitors Host targets" exact="Serine" post="proteases Structure-based drug design Introduction At present, 588 human"/>
 <result pre="(Turk 2006), as well as the neprilysin (enkephalinase) inhibitor prodrugs" exact="sacubitril" post="(Howell and Cameron 2016) and racecadotril (acetorphan) target Zn2+-dependent"/>
 <result pre="and racecadotril (acetorphan) target Zn2+-dependent metalloproteases. The ACE blockers and" exact="sacubitril" post="are suitable for long-term usage as antihypertensive drugs, whereas"/>
 <result pre="can be used as anticoagulants (Straub et al. 2011). Except" exact="argatroban" post="and bivalirudin, all of these clotting protease inhibitors are"/>
 <result pre="to an enhanced insulin secretion (Scheen 2015). The proteasome inhibitors" exact="bortezomib" post="(Adams 2004) and carfilzomib (Kortuem and Stewart 2013) are"/>
 <result pre="secretion (Scheen 2015). The proteasome inhibitors bortezomib (Adams 2004) and" exact="carfilzomib" post="(Kortuem and Stewart 2013) are used in patients with"/>
 <result pre="is an important prerequisite for a rational structure-based drug design." exact="Serine" post="Proteases as Antiviral Targets Trypsin-Like Serine Proteases The majority"/>
 <result pre="rational structure-based drug design. Serine Proteases as Antiviral Targets Trypsin-Like" exact="Serine" post="Proteases The majority of the human serine proteases belongs"/>
 <result pre="very specific protease with a strong preference for substrates with" exact="glycine" post="in P2 position due to the presence of a"/>
 <result pre="factor Xa substrates (Oe et al. 2016); both possess a" exact="glycine" post="in P2 position. Moreover, in rats and mice, cellular"/>
 <result pre="studies a weak antiviral effect after treatment with ECA (5," exact="ε-aminocaproic acid," post="Fig. 11.4) was observed in mice infected by IAV"/>
 <result pre="active-site titrant p-nitrophenyl-p-guanidinobenzoate (Chase and Shaw 1967) including compounds like" exact="camostat" post="8 (FOY-305) and nafamostat 9 (FUT-175) (Fujii and Hitomi"/>
 <result pre="and Shaw 1967) including compounds like camostat 8 (FOY-305) and" exact="nafamostat" post="9 (FUT-175) (Fujii and Hitomi 1981) inhibit numerous trypsin-like"/>
 <result pre="and the circulation (t½ &amp;lt;1 min after intravenous application of" exact="camostat" post="in man (Midgley et al. 1994)). A very short"/>
 <result pre="although this could be an advantage for certain applications. Notably," exact="nafamostat" post="has been widely used as anticoagulant for hemodialysis patients"/>
 <result pre="in a short antiparallel β-sheet interaction with a highly conserved" exact="glycine" post="in position 216 of the protease domain, irrespective of"/>
 <result pre="nM (Schweinitz et al. 2006)) due to the presence of" exact="glycine" post="in P2 position but inhibits also trypsin and matriptase"/>
 <result pre="the aromatic residues Tyr99, Phe174, and Trp215 The replacement of" exact="glycine" post="by proline in P2 position leads to the relatively"/>
 <result pre="1999) (WX-UK1, Fig. 11.9) in combination with the 5-fluorouracil prodrug" exact="capecitabine" post="reached clinical development for tumor therapy (Setyono-Han et al."/>
 <result pre="et al. 2013), respectively. Surprisingly, also the mucolytic cough suppressant" exact="bromhexine" post="30 was described as TMPRSS2 inhibitor (IC50 = 0.75"/>
 <result pre="by a combination treatment with the broad-spectrum serine protease inhibitor" exact="camostat" post="(8) (Fig. 11.4) and the cathepsin inhibitor (23,25) trans-epoxysuccinyl-"/>
 <result pre="(8) (Fig. 11.4) and the cathepsin inhibitor (23,25) trans-epoxysuccinyl- l-leucylamido-3-methyl-butane" exact="ethyl ester" post="(EST) (Kawase et al. 2012). Based on these observations,"/>
 <result pre="spread and pathogenesis were only prevented by the TLSP inhibitor" exact="camostat" post="and not by broad-spectrum vinylsulfone-type cysteine protease inhibitors targeting"/>
 <result pre="plasmin. Further modification of the P3 position by tert-leucine or" exact="penicillamine" post="provided inhibitors with enhanced potencies (Becker et al. 2011;"/>
 <result pre="their amide precursors with borane-tetrahydrofuran provided a series of multibasic" exact="piperazine" post="and pyrrolidine containing derivatives, like 45 (Fig. 11.19) with"/>
 <result pre="prepared by replacement of its leucyl-agmatine segment. The more hydrophobic" exact="ethyl ester" post="prodrug E-64d (60) reached clinical phase III trials (Satoyoshi"/>
 <result pre="Rev2014341168121610.1002/med.2131524659483 AndersonEDThomasLHayflickJSThomasGInhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed" exact="alpha" post="1-antitrypsin variantJ Biol Chem199326824887248918227051 AnglikerHSynthesis of tight binding inhibitors"/>
 <result pre="hemagglutinin of H9N2 influenza A virusesJ Virol2013871811182010.1128/JVI.02320-1223192872 BarrettAJStarkeyPMThe interaction of" exact="alpha" post="2-macroglobulin with proteinases. Characteristics and specificity of the reaction,"/>
 <result pre="Commun20144501070107510.1016/j.bbrc.2014.06.10924978308 HammamiMRühmannEMaurerEHeineAGütschowMKlebeGSteinmetzerTNew 3-amidinophenylalanine-derived inhibitors of matriptaseMed Chem Commun2012380781310.1039/c2md20074k HanSJKimHSKimKIWhangSMHongKSLeeWKLeeSHUse of" exact="Nafamostat" post="Mesilate as an anticoagulant during extracorporeal membrane oxygenationJ Korean"/>
 <result pre="oxygenationJ Korean Med Sci20112694595010.3346/jkms.2011.26.7.94521738350 HanZHarrisPKJonesDEChuganiRKimTAgarwalMShenWWildmanSAJanetkaJWInhibitors of HGFA, Matriptase, and Hepsin" exact="Serine" post="Proteases: a nonkinase strategy to block cell signaling in"/>
 <result pre="to block cell signaling in cancerACS Med Chem Lett201451219122410.1021/ml500254r25408834 HanZHarrisPKKarmakarPKimTOwusuBYWildmanSAKlampferLJanetkaJWalpha-Ketobenzothiazole" exact="Serine" post="Protease inhibitors of aberrant HGF/c-MET and MSP/RON Kinase pathway"/>
 <result pre="A Virus Hemagglutinin Is Facilitated by Different Type II Transmembrane" exact="Serine" post="ProteasesJournal of Virology20169094298430710.1128/JVI.02693-1526889029 KwiatkowskaACoutureFLevesqueCLyKBeaucheminSDesjardinsRNeugebauerWDoryYLDayRNovel insights into structure-activity relationships of"/>
 <result pre="cleavage of the hemagglutinin polypeptideVirology19756844045410.1016/0042-6822(75)90285-8128196 LeeMGKimKHParkKYKimJSEvaluation of anti-influenza effects of" exact="camostat" post="in mice infected with non-adapted human influenza virusesArch Virol19961411979198910.1007/BF017182088920829"/>
 <result pre="CD26Nature201350022723110.1038/nature1232823831647 LuYHardesKDahmsSOBöttcher-FriebertshäuserESteinmetzerTThanMEKlenkHDGartenWPeptidomimetic furin inhibitor MI-701 in combination with oseltamivir and" exact="ribavirin" post="efficiently blocks propagation of highly pathogenic avian influenza viruses"/>
 <result pre="of intracellular proteolytic processing of soluble proproteins by an engineered" exact="alpha" post="2-macroglobulin containing a furin recognition sequence in the bait"/>
</results>
